Entities / Company
Pulmonx (United States).
company in Redwood City, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Pulmonx received FDA pre-market approval for a drug and plans to present its findings at a conference in Boston.Some support1 report
-
FDA granted pre-market approval for Zephyr Valve.Some support2 reports2 developments inside
-
Pulmonx appointed Steve Williamson as CEO and expanded treatment centers for Zephyr Valve.Some support1 report
-
Strong adoption of Zephyr valves drove revenue increase for Pulmonx.Some support1 report
-
Pulmonx, a company in the Zacks Medical Info Systems industry, underperformed the S&P 500 market so far.Some support1 report
-
The Relative Strength Index (RSI) for Pulmonx showed a reading of 29.6 on August 5, 2025, suggesting that selling pressure was reaching exhaustion.Some support1 report
-
Pulmonx announced a strategic partnership with Jaeger™ Medical on August 27, 2025, to integrate data qualification, utilizing SentrySuite™ as the industry-leading platform.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Pulmonx (United States) this week
News at the entities that move Pulmonx (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Pulmonx (United States)
Connections
The 2 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Steve Williamson Structural
Steve Williamson serves as the CEO and President of Pulmonx.
-
FDA Structural
The FDA formally regulates Pulmonx, granting pre-market approval for its products.
History
Events by the month they beganJune 2026
7 events- Pulmonx received FDA pre-market approval for a drug and plans to present its findings at a conference in Boston.
- FDA granted pre-market approval for Zephyr Valve.
- Pulmonx appointed Steve Williamson as CEO and expanded treatment centers for Zephyr Valve.
- Strong adoption of Zephyr valves drove revenue increase for Pulmonx.
- Pulmonx, a company in the Zacks Medical Info Systems industry, underperformed the S&P 500 market so far.
- The Relative Strength Index (RSI) for Pulmonx showed a reading of 29.6 on August 5, 2025, suggesting that selling pressure was reaching exhaustion.
- Pulmonx announced a strategic partnership with Jaeger™ Medical on August 27, 2025, to integrate data qualification, utilizing SentrySuite™ as the industry-leading platform.